In an early clinical study, two infants with R/R ALL were successfully treated with universal CAR-T cells, a product in which CD52 and αβ TCR were disrupted through a transcription activator-like effector nuclease (TALEN) gene editing technique [134]. Here, CD52 is linked to acute lymphoblastic leukemia.